Schaper Benz & Wise Investment Counsel Inc. WI Has $16.14 Million Stock Holdings in Abbott Laboratories (NYSE:ABT)

Schaper Benz & Wise Investment Counsel Inc. WI cut its holdings in Abbott Laboratories (NYSE:ABT) by 0.4% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 192,840 shares of the healthcare product maker’s stock after selling 750 shares during the quarter. Abbott Laboratories comprises 2.0% of Schaper Benz & Wise Investment Counsel Inc. WI’s holdings, making the stock its 17th biggest position. Schaper Benz & Wise Investment Counsel Inc. WI’s holdings in Abbott Laboratories were worth $16,135,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Bath Savings Trust Co boosted its position in Abbott Laboratories by 2.7% during the 2nd quarter. Bath Savings Trust Co now owns 52,679 shares of the healthcare product maker’s stock worth $4,430,000 after acquiring an additional 1,375 shares during the last quarter. Cox Capital Mgt LLC boosted its position in Abbott Laboratories by 5.0% during the 2nd quarter. Cox Capital Mgt LLC now owns 20,915 shares of the healthcare product maker’s stock worth $1,759,000 after acquiring an additional 1,002 shares during the last quarter. Thomasville National Bank boosted its position in Abbott Laboratories by 1.6% during the 2nd quarter. Thomasville National Bank now owns 28,673 shares of the healthcare product maker’s stock worth $2,411,000 after acquiring an additional 455 shares during the last quarter. Private Trust Co. NA boosted its position in Abbott Laboratories by 7.0% during the 2nd quarter. Private Trust Co. NA now owns 36,943 shares of the healthcare product maker’s stock worth $3,106,000 after acquiring an additional 2,411 shares during the last quarter. Finally, LVM Capital Management Ltd. MI boosted its position in Abbott Laboratories by 1.2% during the 2nd quarter. LVM Capital Management Ltd. MI now owns 31,146 shares of the healthcare product maker’s stock worth $2,619,000 after acquiring an additional 373 shares during the last quarter. Institutional investors and hedge funds own 73.77% of the company’s stock.

A number of research firms have weighed in on ABT. Jefferies Financial Group upped their price target on Abbott Laboratories from $80.00 to $98.00 and gave the stock a “buy” rating in a research report on Thursday, July 18th. William Blair reaffirmed an “underperform” rating on shares of Abbott Laboratories in a research report on Thursday, October 17th. Zacks Investment Research downgraded Abbott Laboratories from a “buy” rating to a “hold” rating and set a $93.00 price target for the company. in a research report on Wednesday, August 21st. Cowen upped their price target on Abbott Laboratories from $86.00 to $95.00 and gave the stock an “outperform” rating in a research report on Thursday, July 18th. Finally, Morgan Stanley upped their price objective on Abbott Laboratories from $85.00 to $93.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 16th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and thirteen have assigned a buy rating to the company. Abbott Laboratories presently has an average rating of “Buy” and an average target price of $87.61.

Shares of ABT traded up $0.35 during trading hours on Friday, hitting $83.74. 3,462,833 shares of the company were exchanged, compared to its average volume of 5,339,424. The company has a market cap of $145.61 billion, a price-to-earnings ratio of 29.08, a P/E/G ratio of 2.38 and a beta of 1.13. Abbott Laboratories has a fifty-two week low of $65.44 and a fifty-two week high of $88.76. The company has a quick ratio of 1.12, a current ratio of 1.54 and a debt-to-equity ratio of 0.55. The firm’s fifty day moving average is $82.03 and its 200 day moving average is $82.21.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Wednesday, October 16th. The healthcare product maker reported $0.84 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.84. The company had revenue of $8.08 billion for the quarter, compared to analyst estimates of $8.10 billion. Abbott Laboratories had a return on equity of 17.65% and a net margin of 10.50%. Abbott Laboratories’s quarterly revenue was up 5.5% on a year-over-year basis. During the same period in the prior year, the firm posted $0.75 EPS. Analysts anticipate that Abbott Laboratories will post 3.25 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, November 15th. Investors of record on Tuesday, October 15th will be paid a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 1.53%. The ex-dividend date of this dividend is Friday, October 11th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 44.44%.

In related news, SVP Randel William Woodgrift sold 21,000 shares of the firm’s stock in a transaction dated Wednesday, October 23rd. The stock was sold at an average price of $80.54, for a total value of $1,691,340.00. Following the sale, the senior vice president now directly owns 68,562 shares of the company’s stock, valued at $5,521,983.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Joseph J. Manning sold 47,226 shares of the firm’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $85.14, for a total value of $4,020,821.64. Following the completion of the sale, the senior vice president now directly owns 97,755 shares in the company, valued at $8,322,860.70. The disclosure for this sale can be found here. Company insiders own 0.70% of the company’s stock.

About Abbott Laboratories

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon.

Recommended Story: Why do companies issue convertible shares?

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.